Cannabis, CBD and pain: what the trials show
Controlled trials show no effect of CBD on pain: against a placebo, it did no better in osteoarthritis or in neuropathic pain. A CBD product sold in French shops may not claim any effect on pain in any case. Cannabis-based medicines, THC included, follow a separate medical pathway that covers, among other conditions, neuropathic pain resistant to treatment.
Key takeaways
- The 2026 Cochrane review finds no clear evidence that CBD-dominant medicines have an effect on neuropathic pain (5 studies, 208 participants).
- Among 129 patients with hand osteoarthritis, 20 to 30 mg of CBD a day for 12 weeks did no better than a placebo.
- In 2021, the International Association for the Study of Pain declined to endorse the general use of cannabinoids for pain.
- In law, a product presented as acting on a disease becomes a medicine.
What the controlled trials show
The placebo effect is strong in pain, and some participants improve whatever they are given. Only blinded trials that compare CBD with a placebo can show whether it adds anything. The strongest of them all reach the same answer.
| Study | Participants | Product and duration | Result against placebo |
|---|---|---|---|
| Vela et al., Pain, 2022 | 129 patients, hand osteoarthritis or psoriatic arthritis | Synthetic CBD, 20 to 30 mg a day, 12 weeks | Difference of 0.23 mm on a 100 mm scale: no effect |
| CANOA trial, 2025 | 45 patients, knee osteoarthritis | Full-spectrum oil, 45 mg of CBD a day, 60 days | Similar improvement in both groups |
| Cochrane review, 2026 | 5 studies, 208 participants, neuropathic pain | CBD-dominant medicines | No clear evidence of 50% pain relief |
In the Danish Vela trial, pain fell by more than 30 mm out of 100 in 22% of patients on CBD and in 21% of those on placebo. Sleep, anxiety and depression did not change either. The Brazilian CANOA trial tested a full-spectrum cannabis oil in knee osteoarthritis. The two groups improved by the same amount, and secondary outcomes, sleep included, did not differ.
The Cochrane review updated in 2026 pooled 21 trials with 2,187 participants who had neuropathic pain, the kind caused by nerve damage. It found no clear evidence of an effect for THC-dominant medicines or for CBD-dominant ones. Products combining THC and CBD slightly raise the share of patients reaching 30% pain relief, with low certainty and an effect the authors consider not clinically relevant.
Across all cannabinoids, a meta-analysis of 65 trials with 7,017 participants, published in 2023, found that chronic pain fell by 0.43 points on a 10-point scale. The authors place that below the threshold a patient would notice, and the gain comes with more side effects. In 2021, the International Association for the Study of Pain (IASP) concluded that, for lack of good-quality evidence, it could not endorse the general use of cannabinoids to treat pain.
Why a CBD product cannot promise anything
Under article L5111-1 of the Public Health Code, French law classes as a medicine any product "presented as having curative or preventive properties with regard to human diseases". This is the rule of the medicine by presentation: whatever it contains, an oil sold "for pain" becomes an unauthorised medicine. MILDECA, the French government's drug agency, notes that CBD products may not make therapeutic claims, on pain of criminal penalties.
Each product family is covered by its own text:
| Product | Applicable text | What is excluded |
|---|---|---|
| Oil or capsule to swallow | Regulation (EU) No 1169/2011, article 7 | Attributing to a food the property of preventing, treating or curing a disease |
| Balm, cream, massage oil | Regulation (EC) No 1223/2009, article 2 | Any function other than cleaning, perfuming, changing the appearance of, protecting or keeping the skin in good condition |
| All products | Public Health Code, article L5111-1 | Being presented as acting on a disease |
A CBD cosmetic may therefore speak about the skin: moisture, texture, how it feels during a massage. Joints, muscles and pain lie outside the definition of a cosmetic, so it may not mention them. Regulation (EU) No 655/2013 also requires every cosmetic claim to rest on adequate, verifiable evidence. Our guide to assessing a CBD cream or balm explains how to read a label.
Medical cannabis, a separate pathway
Cannabis-based medicines are unrelated to the CBD products sold in shops. They may contain THC, a doctor prescribes them, and the ANSM, the French medicines agency, monitors them. The order of 16 October 2020 set out the five situations covered by the French trial programme, two of them concerning pain: "neuropathic pain refractory to accessible (drug or non-drug) therapies" and "painful spasticity in multiple sclerosis".
The programme ended on 31 December 2024. The ANSM page, updated in April 2026, says that patients already enrolled continue their treatment in a transition phase, which will close three months after the French National Authority for Health publishes its opinion. Under the planned framework, these medicines are reserved for cases where existing treatments have failed, with the first prescription made in hospital. The timetable is followed in our update on medical cannabis.
Epidyolex, the only authorised CBD medicine, is indicated for rare childhood epilepsies and has no indication for pain.
If you already use a CBD product
A CBD product is no substitute for a pain treatment. A few points help you avoid bad surprises:
- When swallowed, CBD interacts with medicines. It is broken down by liver enzymes that also process many treatments, as explained in CBD's grapefruit effect. Talk to your doctor or pharmacist, particularly if you take an anticoagulant or an anti-epileptic.
- A label promising an effect on pain should put you on guard, because it shows the seller is not following the law.
- The certificate of analysis tells you what the product contains, CBD and THC included, and our guide to reading a certificate of analysis goes through each line.
Pain that persists, worsens or keeps you awake warrants a medical appointment. Your GP can look for a cause and, if needed, refer you to a specialist pain clinic. Our articles on osteoarthritis and fibromyalgia take conditions often linked with CBD one by one.
Frequently asked questions
Controlled trials have not shown it. CBD did no better than a placebo in hand and knee osteoarthritis or in neuropathic pain, and no health authority recognises it as a painkiller.
Not to new patients in 2026. Only those enrolled in the trial programme continue their treatment during the transition phase. The final framework plans a first prescription in hospital, as a last resort, in particular for refractory neuropathic pain.
No. A cosmetic may only claim an action on the skin, and under article L5111-1 a product presented as acting on a disease becomes a medicine. A seller making such a claim risks penalties.
Only after talking to your doctor or pharmacist. Taken by mouth, CBD is broken down by the same liver enzymes as many medicines, which can alter their blood levels. Never stop a prescribed treatment to replace it with CBD.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.